相关实验视频
Updated: Jan 13, 2026

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
7.0K
合成,抗抑郁药物评价和对替代性pyrazoles作为选择性MAO-A抑制剂的计算见解
Diksha Choudhary1, Rajwinder Kaur1, Kailash Jangid2
1Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India.
European journal of medicinal chemistry
|January 10, 2026
概括
新的皮拉衍生物VK16和VK19通过抑制MAO-A,显示出强大的抗抑郁作用. 这些化合物表现出可逆抑制和有利的特性,使它们成为进一步临床开发的有希望的候选者.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抑郁症是一种普遍存在的情绪障碍,治疗选择有限.
- 单胺氧化酶A (MAO-A) 是抗抑郁药物开发的关键目标.
- 需要新的化学支架来发现有效和安全的抗抑郁药剂.
研究的目的:
- 设计,合成和评估新型pyrazole衍生物作为潜在的抗抑郁药物.
- 研究这些化合物对MAO-A的抑制活性.
- 通过体外和体外模型和计算研究来评估它们的抗抑郁疗效.
主要方法:
- 皮拉衍生物的合成和光谱表征.
- 在体外MAO-A抑制测定和可逆性研究.
- 在动物模型中进行体内强迫游泳试验 (FST) 和尾部悬浮试验 (TST).
- 在分析包括分子对接,分子动力学 (MD) 模拟和密度函数理论 (DFT) 研究.
- 评估抗氧化物质的特性和ADME的概况.
主要成果:
- 化合物VK16和VK19表现出强大且可逆的MAO-A抑制,IC50值与标准值相当.
- 在体内研究 (FST,TST) 支持VK16和VK19.1的抗抑郁作用.
- 分子对接和MD模拟表明在MAO-A活性部位内VK16和VK19的强结合相互作用.
- 化合物表现出有利的ADME特性,包括良好的血脑屏障透.
结论:
- 皮拉衍生物VK16和VK19是具有显著抗抑郁作用的有效可逆MAO-A抑制剂.
- 这些化合物具有有前途的药理学和药理动力学特征.
- VK16和VK19是潜在的新型抑郁症治疗候选药物,需要进一步的临床研究.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
791
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
791
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K

